Company
OncoSil Medical Ltd
ASX:OSL
OncoSil Medical is a global medical device company focused on Interventional Oncology. The company's mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.
61 stories · page 1 of 4
NWR Communications virtual health and biotech conference starts today
The two-day Virtual Small Cap Conference is on today and Monday featuring health, biotech and medtech companies.
OncoSil Medical attracts $16.7 million for breakthrough pancreatic cancer radiation treatment
OncoSil is a first in class medical device for the treatment of unresectable locally advanced pancreatic cancer.
OncoSil Medical seen as undervalued by broker following success with pancreatic cancer treatment trials
The global target market for pancreatic and liver cancer is estimated to be about US$3.5 billion.
OncoSil Medical reveals positive data from pancreatic cancer clinical study
100% disease control rate achieved by the company's device at week 8.
OncoSil Medical gets ready to present pancreatic cancer clinical study data
More concentrated and localised beta radiation compared to external beam radiation.
OncoSil Medical continues to advance its pancreatic cancer study
10 subjects in the study group have now been successfully implanted with the device.
OncoSil Medical achieves steady progress in pancreatic cancer study
A CE Mark application to commercially sell OncoSil™ in Europe is under review.
OncoSil Medical wins key approval
OncoSil is focused on treatments for pancreatic and liver cancer.
Oncosil Medical attracts broker attention
Oncosil has enrolled the first patient in the OncoPac-1 trial.
OncoSil Medical crosses a milestone in global pancreatic cancer study
Recruited the first subject for a global study of OncoSil™ device.
OncoSil Medical outlines timeline for CE Mark
OncoSil is well positioned to collect the supplemental data quickly.
OncoSil Medical Ltd updates on Pancreatic Cancer Clinical Study
Daniel Kenny, chief executive officer, commented: "I am are delighted with the participation of these four prestigious centres in our global clinical program."
OncoSil Medical Ltd: Broker boosts price target
OncoSil Medical Ltd has been receiving a lot of broker attention recently.
OncoSil Medical Ltd's well-funded and delivering milestones
OncoSil Medical Ltd (ASX:OSL) ended the September quarter with $13.8 million in cash, and during the period delivered milestones.
OncoSil Medical Ltd receives a Buy recommendation
OncoSil has received a Buy rating and $0.42 per share price target from Wilsons Research.
OncoSil Medical Ltd swells cash position after tax refund
OncoSil is a clinical-stage medical device company seeking to provide a new medical radiation treatment for cancer subjects.
OncoSil Medical Ltd completes key step towards commercial sales
The manufacturing, supply chain validation and delivery to clinical and commercial centres of the OncoSil product is a key step to commercial sales and the treatment of patients in the OncoPac-1 study.